Ms. Sapinoso has served as our Senior Vice President of Quality since 2023. Prior to joining IGM, Ms. Sapinoso was previously Senior Vice President of Global Quality at Abzena and Vice President of Quality and Regulatory Affairs at Aji BioPharma. Ms. Sapinoso has served in senior Quality leadership roles at global drug development and manufacturing organizations supporting biologics drug substance and drug product operations, and provided leadership across Quality functions including Quality Assurance, Quality Control, and Validation. Ms. Sapinoso has also developed phase appropriate quality systems within manufacturing organizations to advance them from clinical development to commercial approval. In her 26 years in Quality, she has led manufacturing facilities through successful regulatory site inspections resulting in eleven commercial facility and product approvals. Ms. Sapinoso received a B.S. in Biology from De La Salle University, and an M.B.A. from the University of California, Los Angeles with a specialization in Corporate Governance.
Archives: Team Members
Team Member
Faraz Siddiqui
Mr. Siddiqui joined us in 2023 and serves as our Senior Vice President, Manufacturing Operations. Mr. Siddiqui has over 25 years of experience in the biotech/pharmaceutical industry with extensive expertise in manufacturing strategy and operations, CMC development and cross-functional leadership. He joins us most recently from Instil Bio where he was the Vice President, Process Development and Manufacturing operations in the US and UK for a TIL therapy targeting multiple solid tumors. He established and led the global process development and manufacturing operations which included CMC strategy, development, transfers and filings to multiple Health Authorities. He also spent 3 years at Kite Pharma as Senior Director of Technology Excellence within Process Development, where he was responsible for technology transfers, technology development and process development business operations. Prior to that, he spent 19 years at Roche/Genentech in various roles of increasing responsibilities in internal and external manufacturing as well as leading global biologics technology transfers across the Roche network. Mr. Siddiqui has a B.S. in Biochemistry from UC Davis and an M.B.A from St. Mary’s College of California.
Angus M. Sinclair, Ph.D.
Dr. Sinclair joined us in 2018 and is our Executive Vice President of Research. Prior to joining IGM, Dr. Sinclair served as Senior Director, Oncology Research at Northern Biologics, a biotechnology company, from 2015 to 2018. He also previously served in various scientific and leadership positions at Amgen, including most recently as Scientific Director, Oncology Research, from 2011 to 2015. Dr. Sinclair received a B.Sc. in Molecular Biology from the University of Edinburgh and a Ph.D. in Hematology/Molecular Biology from the National Institute for Medical Research/University College London.
Steven Weber
Mr. Weber joined us in 2022 and serves as our Senior Vice President, Corporate Controller and Principal Accounting Officer. Prior to joining IGM, Mr. Weber served as Vice President and Principal Accounting Officer at Aeglea Biotherapeutics, a public, clinical-stage biotechnology company. Prior to Aeglea, he held controller and finance leadership roles at SACHEM, American Campus Communities and Citco Fund Services. Mr. Weber began his career as a public accountant at PricewaterhouseCoopers and is a certified public accountant in the state of Texas. He received a B.B.A. in Accounting and an M.P.A. from the McCombs School of Business at the University of Texas at Austin.
Felix J. Baker, Ph.D.
Dr. Baker has served as a member of our board of directors since January 2021. Dr. Baker is a Managing Member of Baker Bros. Advisors LP (“BBA”), a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations. Dr. Baker founded BBA, together with his brother Julian Baker, in 2000. Dr. Baker has served on the boards of biotechnology and pharmaceutical companies, including Seagen since July 2003, Talis Biomedical since July 2013, Kodiak Sciences since September 2015, and Kiniksa Pharmaceuticals since October 2015, and he previously served on the board of Alexion Pharmaceuticals from June 2015 to February 2021. Dr. Baker holds a B.S and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.
M. Kathleen Behrens, Ph.D.
Dr. Behrens has served as a member of our board of directors since January 2019. Since December 2009, Dr. Behrens has served as an independent life sciences consultant and investor. From January 2012 to June 2014, she served as the Co-Founder, President, Chief Executive Officer and director of the KEW Group, a private oncology services company. From 1996 to December 2009, Dr. Behrens served in various roles at RS Investments, an investment management and research firm, including as a General Partner for selected venture funds. Prior to this, from 1983 to 1996, she served as a General Partner and Managing Director at Robertson Stephens & Co. Since March 2009, Dr. Behrens has served as a member of the board of directors of Sarepta Therapeutics, a medical research and drug development company, and as Chairwoman since April 2015, as well as Chair of its audit committee and a member of its research and development committee. She has served as Chairwoman of the board of directors of MiMedx Group, a biomedical company, since June 2019, and as a member of its nominating and governance committee and audit committee. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biopharmaceutical company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. She previously served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. She has also spent time as a public-market biotechnology securities analyst and a venture capitalist focusing on healthcare, technology and related investments. She also previously served on the Board on Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis.
Julie Hambleton, M.D.
Dr. Hambleton has served as a member of our board of directors since August 2018. Dr. Hambleton served as Interim President & CEO, Arch Oncology, a private company, from August 2020 to March 2021. From June 2018 until her retirement in April 2020, Dr. Hambleton served as Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, an oncology medicine company. From September 2017 to May 2018 and from March 2016 to May 2016, Dr. Hambleton served as an independent strategic consultant for various life sciences companies. From May 2016 to September 2017, she served as Vice President, Head U.S. Medical at Bristol-Myers Squibb, a global biopharmaceutical company. From August 2015 to February 2016, Dr. Hambleton served as Executive Vice President, Chief Medical Officer at Five Prime Therapeutics, a biotechnology company, and as Senior Vice President, Chief Medical Officer from December 2012 to August 2015. From April 2010 to November 2012, Dr. Hambleton served as Vice President, Clinical Development at Clovis Oncology, and from 2003 to 2010, Dr. Hambleton held increasing roles of responsibility in BioOncology at Genentech. Dr. Hambleton has served on the board of directors of SpringWorks Therapeutics, a biopharmaceutical company, since May 2020 and Erasca, Inc., a biotechnology company, since March 2021. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, where she then served on the faculty from 1993 to 2003. Dr. Hambleton received an M.D. from Case Western Reserve University School of Medicine and a B.S. in Nursing from Duke University and was board-certified in Hematology and Internal Medicine.
Mary Beth Harler, M.D.
Dr. Harler joined IGM in 2021. She is our Chief Executive Officer and a member of our Board of Directors. Prior to joining IGM she was Senior Vice President, Head of Immunology and Fibrosis Development at Bristol Myers Squibb, where she oversaw late-stage development of assets for the potential treatment of psoriasis, inflammatory bowel disease (IBD) and nonalcoholic steatohepatitis (NASH), among others. Dr. Harler also oversaw approved medicines within the immunology and fibrosis portfolios, such as Orencia and Zeposia. In her more than 10 years at Bristol Myers Squibb she also served as Head of Innovative Medicines Development and Head of Innovative Clinical Development in the cardiovascular, fibrosis, immunoscience and genetically-defined diseases group. Prior to joining Bristol Myers Squibb, Dr. Harler worked in both medical affairs and clinical research at Wyeth Pharmaceuticals (now part of Pfizer). Dr. Harler received a B.S. from Wheeling University in West Virginia and an M.D. from Marshall University. She completed training as a general surgeon at Brown University’s Rhode Island Hospital, where she was also a research fellow with a focus on the role of immune cells in wound healing.
Michael Lee
Mr. Lee has served as a member of our board of directors since July 2019. Mr. Lee has served as Co-Founder and Portfolio Manager at Redmile Group, an investment advisory firm since 2007. Prior to Redmile, Mr. Lee worked as a biotechnology investor at Steeple Capital, an investment management firm, and as an analyst at Welch Capital Partners, an investment advisory firm, and Prudential Equity Group, a financial services company. Mr. Lee has served on the board of directors of Fate Therapeutics, a biopharmaceutical company, since July 2018 and Shattuck Labs, a biotechnology company, since June 2020. Mr. Lee holds a B.S. in Molecular and Cellular Biology from the University of Arizona.
William Strohl, Ph.D.
Dr. Strohl has served as a member of our board of directors since August 2018. In August 2016, Dr. Strohl founded BiStro Biotech Consulting, a biotechnology consulting company, of which he also serves as President. From February 2016 to August 2016, Dr. Strohl served as Vice President and Biologics Fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research & Development division of Johnson & Johnson, a multinational medical devices and pharmaceutical company, and served as its Vice President and Head from October 2013 to February 2016. Prior to that, from April 2008 to October 2013, Dr. Strohl served as Head of Antibody Discovery at Janssen BioTherapeutics. Dr. Strohl has also held various roles at Merck, a pharmaceutical company, including leading Natural Products Biology and leading Biologics discovery efforts and was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl received a B.S. in Biology from Central Michigan University and a Ph.D. in Microbiology from Louisiana State University.